Načítá se...
Emerging therapies for small cell lung cancer
Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcome...
Uloženo v:
| Vydáno v: | J Hematol Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6498593/ https://ncbi.nlm.nih.gov/pubmed/31046803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0736-3 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|